Indaptus Therapeutics Inc (INDP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) has a cash flow conversion efficiency ratio of -0.169x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.93 Million) by net assets ($11.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Indaptus Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Indaptus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Indaptus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Indaptus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indaptus Therapeutics Inc ranked by their cash flow conversion efficiency. Explore how high is Indaptus Therapeutics Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Transcontinental Inc
TO:TCL-A
|
-0.095x |
|
TruBridge Inc.
NASDAQ:TBRG
|
0.075x |
|
Beetaloo Energy Australia Limited
AU:BTL
|
-0.055x |
|
Silkroad Visual Technology Co Ltd
SHE:300556
|
0.286x |
|
enCore Energy Corp. Common Shares
NYSE MKT:EU
|
-0.073x |
|
Kingsway Corporation
NYSE:KWY
|
0.000x |
|
Valid Soluções S.A
SA:VLID3
|
0.074x |
|
TTS (TRANSPORT TRADE SERVICES)
RO:TTS
|
0.033x |
Annual Cash Flow Conversion Efficiency for Indaptus Therapeutics Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Indaptus Therapeutics Inc from 2008 to 2025. View current stock price of Indaptus Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.15 Million | $-14.82 Million | -4.703x | -50.56% |
| 2024-12-31 | $3.94 Million | $-12.32 Million | -3.124x | -181.42% |
| 2023-12-31 | $12.08 Million | $-13.41 Million | -1.110x | -109.05% |
| 2022-12-31 | $24.63 Million | $-13.08 Million | -0.531x | -68.83% |
| 2021-12-31 | $35.90 Million | $-11.29 Million | -0.315x | -102.25% |
| 2020-12-31 | $-237.70K | $-3.32 Million | 13.987x | +655.47% |
| 2019-12-31 | $11.54 Million | $-29.05 Million | -2.518x | -245.03% |
| 2018-12-31 | $53.55 Million | $-39.08 Million | -0.730x | -93.89% |
| 2017-12-31 | $58.80 Million | $-22.13 Million | -0.376x | +28.82% |
| 2016-12-31 | $22.70 Million | $-12.01 Million | -0.529x | -137.68% |
| 2015-12-31 | $35.63 Million | $-7.93 Million | -0.222x | +55.64% |
| 2014-12-31 | $9.48 Million | $-4.75 Million | -0.501x | -37.70% |
| 2013-12-31 | $9.30 Million | $-3.38 Million | -0.364x | +44.59% |
| 2012-12-31 | $6.85 Million | $-4.50 Million | -0.657x | +5.12% |
| 2011-12-31 | $7.77 Million | $-5.38 Million | -0.693x | -84.96% |
| 2010-12-31 | $11.51 Million | $-4.31 Million | -0.375x | +80.86% |
| 2009-12-31 | $1.57 Million | $-3.08 Million | -1.957x | -208.82% |
| 2008-12-31 | $-2.10 Million | $-3.78 Million | 1.798x | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more